{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T07:40:08Z","timestamp":1746776408346,"version":"3.40.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013738","name":"Pacira Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.diagmicrobio.2022.115785","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T02:06:05Z","timestamp":1658973965000},"page":"115785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pathogens susceptible to tetracycline are also susceptible to omadacycline: tetracycline as a one-sided surrogate to predict omadacycline susceptible pathogens"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-6320","authenticated-orcid":false,"given":"Alisa W.","family":"Serio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany R.","family":"Keepers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0002","doi-asserted-by":"crossref","first-page":"e01270","DOI":"10.1128\/JCM.01270-19","article-title":"Bringing antimicrobial susceptibility testing for new drugs into the clinical laboratory: Removing obstacles in our fight against multidrug-resistant pathogens","volume":"57","author":"Kirby","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0003","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: CLSI supplement M100. 31st ed. Wayne, PA; 2021."},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0004","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.2217\/fmb-2017-0106","article-title":"Susceptibility testing and reporting of new antibiotics with a focus on tedizolid: an international working group report","volume":"12","author":"Wilcox","year":"2017","journal-title":"Futur Microbiol"},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0005","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/AAC.01066-13","article-title":"Mechanism of action of the novel aminomethylcycline antibiotic omadacycline","volume":"58","author":"Draper","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0006","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1128\/AAC.01536-15","article-title":"Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline","volume":"59","author":"Honeyman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0007","unstructured":"NUZYRA. [package insert]. 2021:King of Prussia, PA: Paratek Pharmaceuticals, Inc."},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0008","unstructured":"US Food and Drug Administration. Omadacycline injection and oral products. https:\/\/www.fda.gov\/drugs\/development-resources\/omadacycline-injection-and-oral-products. Accessed November 19, 2021."},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0009","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2013.01.023","article-title":"Contemporary tetracycline susceptibility testing: Doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive spathogens","volume":"76","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0010","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.diagmicrobio.2013.01.022","article-title":"Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria","volume":"75","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0011","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th Ed. M07. Wayne, PA; 2018."},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0012","doi-asserted-by":"crossref","first-page":"e00018","DOI":"10.1128\/AAC.00018-17","article-title":"Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.02.017","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017","volume":"19","author":"Huband","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0014","doi-asserted-by":"crossref","first-page":"e02488","DOI":"10.1128\/AAC.02488-19","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016-2018","volume":"64","author":"Pfaller","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgar.2021.09.011","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States: Report from the SENTRY Antimicrobial Surveillance Program, 2019","author":"Pfaller","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0016","unstructured":"Clinical and Laboratory Standards Institute. Development of in vitro susceptibility testing criteria and quality control parameters: CLSI guideline M23. 4th ed. Wayne, PA; 2016."},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0017","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","article-title":"In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline","volume":"58","author":"Macone","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0018","unstructured":"JMI Laboratories Inc. Paratek Keystone Surveillance. https:\/\/paratek-keystone.com\/. Accessed February 3, 2022."},{"key":"10.1016\/j.diagmicrobio.2022.115785_bib0019","unstructured":"Clinical and Laboratory Standards Institute. CLSI rationale document - doxycycline and tetracycline breakpoints for streptococcus pneumoniae; 2013."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889322001511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889322001511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T07:18:27Z","timestamp":1746775107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889322001511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0732889322001511"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2022.115785","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogens susceptible to tetracycline are also susceptible to omadacycline: tetracycline as a one-sided surrogate to predict omadacycline susceptible pathogens","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2022.115785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115785"}}